To date, trials of hESC-derived products are underway in several conditions, including macular degeneration, type I diabetes mellitus (for re-establishing insulin-secreting beta cells), spinal cord injury, and heart failure,39 with the limited results published so far demonstrating their safety.40 This evidence concerns the gene INS and macular degeneration.